Dent is taking part in an observational study called the ADNI3 Trial. This historic study of brain aging could help change the future of Alzheimer’s disease.
We are looking for volunteers between 55 and 90 years of age to participate in the ADNI3 trial.
Poor memory is often viewed as a simple sign of getting older, complicating our understanding and treatment of Alzheimer’s disease. For more than a decade, ADNI researchers have worked tirelessly to better understand the disease and its progression in a way that will help the development of future treatment options. We can only do this with the help of volunteers like you.
The ADNI3 Trial will last for about 5 years, and will involve regular visits to the trial site. Each participant will need a trial partner to attend clinic visits and provide information to the trial team.
Alzheimer’s disease is the sixth leading cause of death overall in the United States and affects more than 5 million Americans. According to experts, this number could triple to nearly 16 million people by 2050. A momentous scientific study focused on early detection of Alzheimer’s disease, and tracking it over time, seeks healthy volunteers without memory problems, as well as people who have mild memory problems, and those who have been diagnosed with mild dementia due to Alzheimer’s disease.
The prestigious Alzheimer’s Disease Neuroimaging Initiative—or ADNI—funded by the National Institutes of Health, is one of the largest and longest running Alzheimer’s disease trials in history. Now in the third phase of trials, researchers are studying how quickly things like reasoning and the ability to perform certain functions change in the aging brain. Researchers need to better understand the disease progression in order to speed the pace of discovery in the race to prevent, treat and cure Alzheimer’s disease.
“It is extremely important that more people get involved in the fight against Alzheimer’s disease, which affects nearly all of us in some way,” said Michael Weiner, MD, principal investigator of the study. “We need to know how Alzheimer’s disease progresses, in order to discover new treatments that could significantly improve the way we treat it in the future.”
The study uses state-of-the-art imaging to monitor brain levels of two proteins called tau and amyloid, both of which are significant indicators of Alzheimer’s disease. Researchers track cognitive function through computer tests at home and in a doctor’s office, which includes measuring changes in one’s ability to handle money, a common warning sign of the disease.
“One of the biggest challenges researchers face is finding people to volunteer to take part in studies,” said Weiner. “We can beat Alzheimer’s, but we can’t do it without volunteers. We need help.”
The ADNI Study needs 800 people to enroll in sites across the United States and in Canada. Researchers are looking for people between the ages of 55 and 90 who have normal thinking and memory function, as well as those who have mild memory problems and those who have been diagnosed with mild dementia due to Alzheimer’s disease. No medication is involved.
- The age of 55 – 90 years old
- Are in good health
- Have little to no memory concerns or have a diagnosis of early Alzheimer’s disease or Mild Cognitive Impairment (MCI)
- Have a study partner who can accompany you to all clinic visits
What to Expect:
- Free Study
- No Medication Involved
The trial is being run by a team that will include doctors and nurses, and may include other healthcare professionals. This is a free study, and no medication will be involved.
Please contact us today for additional information if you think you, or someone you know, can help us with this important research. By contacting us, you are under no obligation to take part in the trial. We look forward to hearing from you soon.
or visit www.ADNI3.org
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.